Danish pharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Thursday that it has entered a strategic research collaboration with Iambic Therapeutics, a medical technology company, to discover a small molecule therapeutic for migraine treatment.

The agreement includes an upfront payment, performance-based milestones and royalties. Iambic Therapeutics, using its AI-driven discovery platform, is advancing an internal pipeline of candidates, including IAM1363, a selective brain-penetrant inhibitor in Phase 1/1b trials and other innovative oncology programs.

This partnership aligns with Lundbeck's strategy to innovate in brain health and aims to leverage generative AI to enhance drug discovery success and efficiency.